STEVENSON, Md., March 14, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Sito Mobile, Ltd. (Nasdaq:SITO) (“Sito” or the “Company”) common stock during the period between February 9, 2016, and January 2, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 18, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Sito common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Sito’s growth of bookings would not propel the Company’s fourth fiscal quarter 2016 media placement revenues and revenue growth to the level represented, Sito was aware that the election would impact the Company’s fourth fiscal quarter 2016 revenue, clients’ campaign spending and media placement revenues in the fourth quarter 2016 was highly dependent on the elections, and the Company’s growth in media placement revenues would not occur in the fourth fiscal quarter 2016.
According to the complaint, following a January 3, 2017 press release announcing that the fourth quarter was negatively affected by restrained advertising spending during a period of heightened and elongated media focus on the election, the value of Sito shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Sito common stock purchased on or after February 9, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 



